- Trials with a EudraCT protocol (1,307)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,307 result(s) found for: Bone scan.
Displaying page 7 of 66.
EudraCT Number: 2005-005766-36 | Sponsor Protocol Number: | Start Date*: 2006-11-17 |
Sponsor Name:Sofamor - Danek | ||
Full Title: A Randomized Prospective Study of Instrumented Posterior Lumbar Interbody Fusion: Autologous Iliac Crest Bone Graft vs. Inductos™ | ||
Medical condition: We will investigate if the use of Inductos in a intervertebral cage will provide us with better and or faster fusion rates. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003228-39 | Sponsor Protocol Number: D4320C00033 | Start Date*: 2008-02-25 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metasta... | ||
Medical condition: hormone-resistant prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Prematurely Ended) NL (Completed) GB (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) PT (Prematurely Ended) HU (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-002944-10 | Sponsor Protocol Number: c16174 | Start Date*: 2019-02-27 |
Sponsor Name:Memorial Sloan Kettering Cancer Center | ||
Full Title: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) | ||
Medical condition: Patients with histological or cytological proof of Metastatic Castration-Resistant Prostate Cancer (mCRPC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Trial now transitioned) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001162-10 | Sponsor Protocol Number: EUOG2014-002 | Start Date*: 2015-05-06 | |||||||||||
Sponsor Name:European Uro- Oncology Group (EUOG) | |||||||||||||
Full Title: An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Hormono-Naïve patients with Metastatic Prostate ... | |||||||||||||
Medical condition: Patients with Metastatic Prostate Cancer who have never been treated with Androgen Deprivation Therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001161-27 | Sponsor Protocol Number: EUOG2014-001 | Start Date*: 2015-05-18 | |||||||||||
Sponsor Name:European Uro- Oncology Group (EUOG) | |||||||||||||
Full Title: An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Chemo-Naïve patients with Progressive Prostate C... | |||||||||||||
Medical condition: Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004429-17 | Sponsor Protocol Number: CO39303 | Start Date*: 2018-09-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/... | |||||||||||||
Medical condition: Metastatic Castrate-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NO (Completed) PT (Completed) DE (Completed) DK (Completed) HU (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IE (Completed) BE (Completed) ES (Ongoing) GR (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003969-19 | Sponsor Protocol Number: CAAA617B12302 | Start Date*: 2021-05-28 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: PSMAfore : A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive ... | |||||||||||||
Medical condition: PSMA-positive metastatic castration-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SK (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000674-30 | Sponsor Protocol Number: 2013-000674-30 | Start Date*: 2013-07-24 |
Sponsor Name:AOU SAN LUIGI GONZAGA - SCDU ONCOLOGIA MEDICA | ||
Full Title: Multicenter clinical trial, randomized phase II "window of opportunity" which aims to test the biological activity of abiraterone acetate administered as neoadjuvant therapy in patients with prosta... | ||
Medical condition: PROSTATE CANCER PATIENTS WITH HIGH RISK | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002355-14 | Sponsor Protocol Number: GBG36 | Start Date*: 2004-11-19 |
Sponsor Name:GBG Forschungsgesellschaft mbH | ||
Full Title: A randomized, multicenter, open phase III study comparing the postoperative use of zoledronic acid versus no treatment in patients with histological tumor residuals after preoperative anthracycli... | ||
Medical condition: Patients with histological tumor residuals after preoperative anthracycline and taxane containing chemotherapy for primary breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002154-39 | Sponsor Protocol Number: VINFORCE007 | Start Date*: 2014-10-23 | |||||||||||
Sponsor Name:Vinforce - Institut für Osteoporoseforschung [...] | |||||||||||||
Full Title: Teriparatide for fracture repair in humans: A prospective, randomized, double-blind placebo-controlled pilot study in female and male patients with proximal humerus fracture The TERAFRAP Study | |||||||||||||
Medical condition: Osteoporotic humerus fracture - accelerated fracture repair | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002122-67 | Sponsor Protocol Number: 1211 | Start Date*: 2013-12-05 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration. | |||||||||||||
Medical condition: metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004711-50 | Sponsor Protocol Number: 9785-MA-1001 | Start Date*: 2014-11-24 | |||||||||||
Sponsor Name:Astellas Pharma Europe Ltd | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients... | |||||||||||||
Medical condition: Metastatic Castrate Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) IT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) BE (Completed) FR (Completed) AT (Ongoing) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002113-39 | Sponsor Protocol Number: BAY88-8223/16298 | Start Date*: 2014-10-29 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ... | |||||||||||||
Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004374-15 | Sponsor Protocol Number: PUMA-NER-6201 | Start Date*: 2018-04-13 | |||||||||||
Sponsor Name:Puma Biotechnology, Inc. | |||||||||||||
Full Title: An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis | |||||||||||||
Medical condition: Early Stage HER2+ Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003444-25 | Sponsor Protocol Number: A5481092 | Start Date*: 2022-05-15 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE® ) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REF... | |||||||||||||
Medical condition: recurrent/refractory Ewing sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) SK (Trial now transitioned) HU (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) FR (Trial now transitioned) DE (Ongoing) ES (Ongoing) CZ (Trial now transitioned) NL (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005715-22 | Sponsor Protocol Number: D6990C00001 | Start Date*: 2006-02-21 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone ma... | ||
Medical condition: postmenopausal women with hormone receptor positive early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Prematurely Ended) NO (Completed) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-005950-27 | Sponsor Protocol Number: 202100762 | Start Date*: 2023-03-29 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma | ||
Medical condition: All patients with histologically proven CD30-positive (i.e. > 1% cells) lymphomas who will be treated with brentuximab vedotin, including: Hodgkin lymphoma, T-cell lymphoma, Cutaneous T-cell lympho... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003485-40 | Sponsor Protocol Number: CCR5163 | Start Date*: 2020-10-01 |
Sponsor Name:The Institute of Cancer Research | ||
Full Title: ACTION: Phase I/II Trial of Abiraterone Acetate in Combination with Tildrakizumab (anti-IL23 targeting monoclonal antibody) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) | ||
Medical condition: Metastatic castration resistant prostate cancer | ||
Disease: | ||
Population Age: | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001979-38 | Sponsor Protocol Number: MultiH/BRA/711 (incl. Amendment #2) | Start Date*: 2007-01-15 | |||||||||||
Sponsor Name:Bracco Imaging Deutschland GmbH | |||||||||||||
Full Title: INTRAINDIVIDUAL CROSS-OVER STUDY TO COMPARE MULTIHANCE® AND OMNISCAN® AT A DOSE OF 0.1 MMOL/KGBW IN THE DIFFERENTIAL DIAGNOSIS OF DISC HERNIATION VS. SCAR | |||||||||||||
Medical condition: Intervertebral disc herniation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002467-86 | Sponsor Protocol Number: FinDoke bi/triweekly | Start Date*: 2005-11-10 |
Sponsor Name:Liisa Elomaa | ||
Full Title: A Randomised Multicenter Trial Comparing Docetaxel q2w and Docetaxel q3w in the Treatment of Patients with Metastatic Breast Cancer | ||
Medical condition: Metastatic Breast Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
